ArticleFrontiers in immunology2022

A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants.

Yu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.